Pharmacovigilance enters the FTC biosimilar debate
By Mari Serebrov
Wednesday, February 5, 2014
Seeing the biosimilar debate as a way to improve pharmacovigilance for all biologics, several biosimilar makers are now pushing for state notification regulations that would lead to transparent and more accurate patient health records.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.